Based on the characterization of TME cell infiltration and biological molecular, PR-A was classified as immune-activated phenotype, with abundant immune cell infiltration and survival advantage; PR-B was classified as intermediate phenotype; and PR-C was classified as immune-excluded phenotype, characterized by the low immune response and high tumor purity. The gene discussed is S100A6; the disease is neoplasm.